Basic Information
REWISCA HARD CAPSULES 150MG
CAPSULE
Regulatory Information
SIN15655P
April 2, 2019
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
Company Information
SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
SINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Active Ingredients
Strength: 150.00 mg
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** _Neuropathic pain_ Rewisca is indicated for the treatment of neuropathic pain which includes diabetic peripheral neuropathy and post-herpetic neuralgia in adults. _Epilepsy_ Rewisca is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. _Generalised Anxiety Disorder_ Rewisca is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. _Fibromyalgia_ Rewisca is indicated for the management of fibromyalgia.